NASDAQ:CDIO

Cardio Diagnostics (CDIO) Stock Price, News & Analysis

$0.69
+0.00 (+0.28%)
(As of 02:04 PM ET)
Today's Range
$0.68
$0.73
50-Day Range
$0.69
$1.81
52-Week Range
$0.17
$3.56
Volume
477,048 shs
Average Volume
934,449 shs
Market Capitalization
$14.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.35

Cardio Diagnostics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
92.9% Upside
$1.35 Price Target
Short Interest
Healthy
2.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.50mentions of Cardio Diagnostics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.63 out of 5 stars

Medical Sector

667th out of 918 stocks

Diagnostic Substances Industry

9th out of 12 stocks

CDIO stock logo

About Cardio Diagnostics Stock (NASDAQ:CDIO)

Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois.

CDIO Stock Price History

CDIO Stock News Headlines

AI finds its first serious application
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Cardio Diagnostics Inks Nationwide Telehealth Deal With Navierre
AI finds its first serious application
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Cardio Diagnostics Holdings Inc
See More Headlines
Receive CDIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/29/2024
Next Earnings (Estimated)
7/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:CDIO
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.35
High Stock Price Target
$1.35
Low Stock Price Target
$1.35
Potential Upside/Downside
+82.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-8,380,000.00
Pretax Margin
-49,088.78%

Debt

Sales & Book Value

Annual Sales
$20,000.00
Book Value
$0.14 per share

Miscellaneous

Free Float
15,114,000
Market Cap
$15.98 million
Optionable
Not Optionable
Beta
5.03
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Meeshanthini V. Dogan Ph.D. (Age 35)
    Co-Founder, CEO & Director
    Comp: $307.25k
  • Ms. Elisa Michael Luqman Esq. (Age 60)
    J.D., M.B.A., Chief Financial Officer
    Comp: $275k
  • Dr. Robert A. Philibert M.D. (Age 62)
    Ph.D., Co-Founder, Chief Medical Officer & Director
  • Mr. Timur Dogan Ph.D. (Age 36)
    Chief Technology Officer
  • Ms. Khullani Abdullahi J.D. (Age 40)
    Vice President of Revenue & Strategy

CDIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Cardio Diagnostics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardio Diagnostics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CDIO shares.
View CDIO analyst ratings
or view top-rated stocks.

What is Cardio Diagnostics' stock price target for 2024?

2 Wall Street research analysts have issued 1-year price objectives for Cardio Diagnostics' shares. Their CDIO share price targets range from $1.35 to $1.35. On average, they predict the company's share price to reach $1.35 in the next year. This suggests a possible upside of 92.9% from the stock's current price.
View analysts price targets for CDIO
or view top-rated stocks among Wall Street analysts.

How have CDIO shares performed in 2024?

Cardio Diagnostics' stock was trading at $2.49 on January 1st, 2024. Since then, CDIO stock has decreased by 71.9% and is now trading at $0.6999.
View the best growth stocks for 2024 here
.

Are investors shorting Cardio Diagnostics?

Cardio Diagnostics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 510,400 shares, an increase of 14.8% from the March 31st total of 444,600 shares. Based on an average daily volume of 502,300 shares, the short-interest ratio is currently 1.0 days. Currently, 2.9% of the company's shares are short sold.
View Cardio Diagnostics' Short Interest
.

When is Cardio Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024.
View our CDIO earnings forecast
.

How do I buy shares of Cardio Diagnostics?

Shares of CDIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDIO) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners